U.S. FDA Approves MedMira’s Advanced Reveal® G4 Rapid HIV-1/2 Antibody Test

Halifax, Nova Scotia, 13 December, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR). MedMira Inc. proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States. This achievement marks a significant milestone for MedMira, positioning the company as a key player […]
Update on MedMira’s Regulatory Path in Canada and the USA

Halifax, Nova Scotia, 27 September, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada and the USA for its infectious disease rapid tests. Currently the Company has two submissions filed with Health Canada and one submission with the US FDA. In addition, the Company […]